Search

Displaying results 521 - 530 of 4626 in total
  1. Drug

    Cefdinir

    go.drugbank.com/drugs/DB00535
    ApprovedInvestigational

    Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie.

  2. Drug

    Evening primrose oil

    go.drugbank.com/drugs/DB11358
    ApprovedNutraceutical

    [A33131] Evening primrose oil has been filled for the FDA by Humanetics Corporation on April 2000 to be a new dietary ingredient but its current status is "Inadequate basis for expectation of safety". … [L2845] By Health Canada, evening primrose oil is approved in over-the-counter combination dietary supplements.[L1113] By the EMA, evening primrose oil is approved in herbal preparations.[L2851]

  3. Drug

    Gemcitabine

    go.drugbank.com/drugs/DB00441
    ApprovedInvestigational

    It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. … [L32960] The structure, metabolism, and mechanism of action of gemcitabine are similar to [cytarabine], but gemcitabine has a wider spectrum of antitumour activity.

  4. Drug

    Etesevimab

    go.drugbank.com/drugs/DB15897
    Investigational

    progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns. … [L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for

  5. Drug

    Chloroprocaine

    go.drugbank.com/drugs/DB01161
    ApprovedInvestigational

    Both can be given as intrathecal injections for peripheral and central nerve block, but only the preservative-free formulation can be used for lumbar and caudal epidural blocks. … [A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 for ocular surface anesthesia.[L43387]

  6. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity … [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788]

  7. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  8. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    [A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical … [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605]

  9. Drug

    Daptomycin

    go.drugbank.com/drugs/DB00080
    ApprovedInvestigational

    [A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing … [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]

  10. Drug

    Erythromycin

    go.drugbank.com/drugs/DB00199
    ApprovedInvestigationalVet approved

    [L5245] Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. … Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists